Earnings season for the second quarter of the calendar year has kicked off, and 24/7 Wall St. has put together a preview of some of the Dow Jones Industrial Average (DJIA) companies that are reporting their quarterly results this week. We included the consensus earnings estimates from Thomson Reuters and the stock price and trading history, as well as added some additional color on each.
For more previews of the big earnings in the week ahead, see 8 Key Earnings for the Coming Week.
Be advised that the earnings and revenue estimates may change ahead of the formal reports, and some companies may change reporting dates as well.
JPMorgan
JPMorgan Chase & Co. (NYSE: JPM) will kick off the new earnings season for the big banks Tuesday morning. The consensus estimates call for earnings per share (EPS) of $1.44 and $24.53 billion in revenue. JPMorgan beat estimates last quarter, with numbers roughly equal to the consensus estimates for the second quarter. The stock price rose nearly 12% in the period, the best of any of the big banks. The bank is still shrinking somewhat, but first-quarter results were able to overcome the decline by taking advantage of the volatility in the markets caused by macro events. If JPMorgan can control its expenses, it should have another decent quarter.
Shares were at $67.05 on Friday’s close, in a 52-week trading range of $54.26 to $69.82. The stock has a consensus analyst price target of $71.57.
ALSO READ: 5 Big Defensive Dividend Stocks to Buy Trading at Deep Discounts
Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) is scheduled to reveal its second-quarter results on Tuesday. The consensus estimates call for $1.69 in EPS, as well as $17.76 billion in revenue. The company is one the top market cap stocks in the health care sector, and it will raise the dividend for shareholders this year for the 52nd consecutive year. With everything from medical devices to over-the-counter health items and prescription drugs, Johnson & Johnson remains one of the most diversified health care names on Wall Street. It also has one of the most exciting pipelines of new drugs in the sector. That all makes the stock an outstanding holding.
Shares were trading at $99.53 on Friday’s close. The consensus price target is $109.59. The stock has a 52-week trading range of $95.10 to $109.49.
Intel
Intel Corp. (NASDAQ: INTC) is set to report its second-quarter results on Wednesday. The analysts’ consensus estimates call for EPS of $0.51 and $13.11 billion in revenue. This top chip company has been in the doghouse on Wall Street all year, and the recent earnings implosion at Micron did not help. Intel has among the highest shareholders cash returns at approximately 8%, but it has lagged high-growth specialty chip stocks. The iconic chip giant had a stellar 2014 on the tailwind from continued personal computer and notebook sales, but this year has been a far different story. The stock is down a gigantic 15.8% year to date.
Shares were changing hands at $29.17 on Friday’s close. The consensus price target is $34.14, and the stock has a 52-week trading range of $28.82 to $37.90.
ALSO READ: 6 Oil and Gas Stocks Analysts Want You to Buy Now
Goldman Sachs
Goldman Sachs Group Inc. (NYSE: GS) is scheduled to report its second-quarter results on Thursday. The consensus analyst estimates call for $3.92 in EPS and revenue of $8.81 billion. First-quarter 2015 EPS totaled $5.94, an upside surprise of nearly 40%. Goldman’s stock was the second best performer among the big banks in the quarter, with a gain of just over 11%. Much depends of the performance of Goldman’s fixed income group, where revenues may drop as much as 15%. On the plus side, mergers and acquisitions fees should improve, and the bank’s investing and lending revenues are expected to rise.
Shares of Goldman Sachs ended last week at $207.19. The consensus price target is $216.00. The 52-week trading range is $162.38 to $218.77.
UnitedHealth
UnitedHealth Group Inc. (NYSE: UNH) is set to share its latest quarterly earnings on Thursday. The consensus estimates call for EPS of $1.59 and $35.66 billion in revenue. Mergers started to fall into place in the health insurance sector when Aetna and Humana announced that they had entered into a definitive agreement. This takes two companies off the table, leaving only Anthem and Cigna left as possible acquisition targets for UnitedHealth.
Shares closed at $122.15 late Friday, in a 52-week trading range of $78.74 to $124.11. The stock has a consensus analyst price target of $141.42.
ALSO READ: 5 Fresh Dividend Hikes Too Important to Ignore
GE
General Electric Co. (NYSE: GE) is set to report its second-quarter results on Friday. The analysts’ consensus estimates call for EPS of $0.30 and $28.71 billion in revenue. 24/7 Wall St. included GE as one of its top 10 stocks to own for the next decade. This company is a highly diversified, global industrial corporation. GE has begun the process of scaling back many of its operations and returning capital to shareholders. The company recently announced a restructuring plan that includes buying back up to $50 billion of its shares, selling about $30 billion in real estate assets over the next two years and divesting more GE Capital operations.
Shares of GE were changing hands at $26.27 as last week’s trading came to a close. The consensus price target is $30.23, and the stock has a 52-week trading range of $23.41 to $28.68.
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.